

072205

18351 U.S. P.

PTO/SB/16 (04-05)

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. **EV 732173837US**3264 U.S. PTO  
60/702077

072205

| INVENTOR(S)                                                                                                                                                                                                                                                                   |                        |                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|---------------------------------------------------------------------------------------------------------------|
| Given Name (first and middle [if any])                                                                                                                                                                                                                                        | Family Name or Surname | Residence<br>(City and either State or Foreign Country)                                                       |
| MARK E.                                                                                                                                                                                                                                                                       | DEEM                   | Mountain View, CA                                                                                             |
| Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto                                                                                                                                                                               |                        |                                                                                                               |
| TITLE OF THE INVENTION (500 characters max)                                                                                                                                                                                                                                   |                        |                                                                                                               |
| SYSTEMS AND METHODS FOR DELIVERY OF A THERAPEUTIC AGENT                                                                                                                                                                                                                       |                        |                                                                                                               |
| Direct all correspondence to: <b>CORRESPONDENCE ADDRESS</b>                                                                                                                                                                                                                   |                        |                                                                                                               |
| <input checked="" type="checkbox"/> The address corresponding to Customer Number: <div style="border: 1px solid black; padding: 5px; display: inline-block;">20350</div>                                                                                                      |                        |                                                                                                               |
| OR                                                                                                                                                                                                                                                                            |                        |                                                                                                               |
| <input type="checkbox"/> Firm or<br>Individual Name                                                                                                                                                                                                                           |                        |                                                                                                               |
| Address                                                                                                                                                                                                                                                                       |                        |                                                                                                               |
| City                                                                                                                                                                                                                                                                          | State                  | Zip                                                                                                           |
| Country                                                                                                                                                                                                                                                                       | Telephone              | Email                                                                                                         |
| <b>ENCLOSED APPLICATION PARTS (check all that apply)</b>                                                                                                                                                                                                                      |                        |                                                                                                               |
| <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76                                                                                                                                                                                                   |                        |                                                                                                               |
| <input type="checkbox"/> CD(s), Number of CDs _____                                                                                                                                                                                                                           |                        |                                                                                                               |
| <input checked="" type="checkbox"/> Specification Number of Pages <u>22</u>                                                                                                                                                                                                   |                        |                                                                                                               |
| <input type="checkbox"/> Other (specify) _____                                                                                                                                                                                                                                |                        |                                                                                                               |
| <input checked="" type="checkbox"/> Drawing(s) Number of Sheets <u>13</u>                                                                                                                                                                                                     |                        |                                                                                                               |
| <b>Application Size Fee:</b> If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).                    |                        |                                                                                                               |
| <b>METHOD OF PAYMENT OF FILING FEES AND APPLICATION SIZE FEE FOR THIS PROVISIONAL APPLICATION FOR PATENT</b>                                                                                                                                                                  |                        |                                                                                                               |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.                                                                                                                                                                                    |                        | TOTAL FEE AMOUNT (\$)<br><div style="border: 1px solid black; padding: 5px; display: inline-block;">100</div> |
| <input type="checkbox"/> A check or money order is enclosed to cover the filing fee and application size fee (if applicable).                                                                                                                                                 |                        |                                                                                                               |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.                                                                                                                                                                                                   |                        |                                                                                                               |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge the filing fee and application size fee (if applicable) or credit any overpayment to Deposit Account Number: <u>20-1430</u> . A duplicative copy of this form is enclosed for fee processing. |                        |                                                                                                               |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.                                                                                                                                       |                        |                                                                                                               |
| <input checked="" type="checkbox"/> No.                                                                                                                                                                                                                                       |                        |                                                                                                               |
| <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____                                                                                                                                                            |                        |                                                                                                               |

[Page 1 of 2]

SIGNATURE \_\_\_\_\_

Date July 22, 2005TYPED or PRINTED NAME James M. HeslinREGISTRATION NO. 29,541TELEPHONE 650-326-2400

(if appropriate)

Docket Number: 020979-003400US**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

60545067 v1

NEURENT 1010

**PROVISIONAL APPLICATION COVER SHEET**  
**Additional Page**

PTO/SB/16 (04-05)

|                                        |                   |                                                         |                 |
|----------------------------------------|-------------------|---------------------------------------------------------|-----------------|
| First Named Inventor                   | DEEM, MARK E.     | Docket Number                                           | 020979-003400US |
| <b>INVENTOR(S)/APPLICANT(S)</b>        |                   |                                                         |                 |
| Given Name (first and middle [if any]) | Family or Surname | Residence<br>(City and either State or Foreign Country) |                 |
| HANSON                                 | GIFFORD           | Woodside, CA                                            |                 |

[Page 2 of 2]

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

60545067 v1

**Provisional**

**PATENT APPLICATION**

**SYSTEMS AND METHODS FOR**

**DELIVERY OF A THERAPEUTIC AGENT**

Inventors:     MARK E. DEEM, a citizen of The United States  
                     residing at 685 Sierra Avenue  
                     Mountain View, California 94041; and

                     HANSON GIFFORD, a citizen of The United States  
                     residing at 3180 Woodside Road  
                     Woodside, California 94062.

Assignee:     The Foundry Inc.  
                     199 Jefferson Drive  
                     Menlo Park, CA 94025

Entity:         Small business concern

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400

## SYSTEMS AND METHODS FOR DELIVERY OF A THERAPEUTIC AGENT

### BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention. The present invention relates to methods and apparatus  
5 for the control of autonomic nerve function comprising delivery via permeabilization of  
targeted cell membranes a therapeutically effective amount of a portion or fragment of  
botulinum toxin (BoNT), the active portion known as the light chain (LC), to cause a clinical  
benefit in various regions within the body.

[0002] First used for medical purposes over 20 years ago for treatment of blepharospasm  
10 and strabismus and other skeletal muscle abnormalities, certain neurotoxins have found  
widespread use in millions of patients worldwide for a variety of conditions.

[0003] Controlled injection of neurotoxins has become a common procedure to control  
skeletal muscle spasms. While the primary application of neurotoxins such as BOTOX®,  
commercially sold by Allergan, Inc. (Irvine, CA), has been focused on cosmetic applications,  
15 such as treatment of facial wrinkles, other uses for the compound are now common. Certain  
applications include treatment of cervical dystonia, tremor, headache (migraine), spasticity,  
torticollis, hemifacial spasm, blepharospasm, meige syndrome, spastic dysphonia, writers  
cramp, hyperhydrosis, hypersalivation, bladder dysfunction multiple sclerosis, spinal cord  
injury, cystic fibrosis, stroke paralysis, stuttering, and all types of pain.

[0004] *Clostridium botulinum* neurotoxins (BoNTs) block the release of acetylcholine from  
20 peripheral cholinergic nerve endings thereby disabling the release of neurotransmitters from  
the cells (Bigalke, H. and Shoer, L.F. (1999) *Clostridial Neurotoxins in Handbook of  
Experimental Pharmacology* 45, 407-443). This mechanism of action is well defined. Seven  
immunologically distinct serotypes of neurotoxin, designated types A through G, have been  
25 identified as discussed by Simpson, L.L., Schmidt, J.J. and Middlebrook, J.L. (1988) in  
*Methods Enzymol.* 165, 76-85. There are general structural and functional similarities among  
the various types of neurotoxins, but they all have preferred recipients, for example some  
favor use in humans and other in non-human species.

[0005] A frequently used neurotoxin for many applications in the human body is  
30 Botulinum Toxin Type A (BoNT\A), a protein produced by the bacterium *Clostridium*

botulinum and sold commercially by Allergan, inc., as BOTOX®. Botulinum toxin blocks the release of neurotransmitter from the nerves that control the contraction of the target muscles. When used in medical settings, small doses of the toxin are injected into the affected muscles and block the release of a chemical acetylcholine that signals the muscle to contract. The toxin thus paralyzes or weakens the injected muscle.

[0006] In addition, use of neurotoxin for control of the following conditions has been proposed in United States Patents 6,063,768 to First, and 5,766,605 to Sanders, including: rhinorrhea, asthma, COPD, excessive stomach acid secretion, spastic colitis, otitis media, arthritis, tenosynovitis, lupus, connective tissue disease, inflammatory bowel disease, gout, tumors, musculo-skeletal abnormalities, reflex sympathetic dystrophies, tendonitis, bursitis, and peripheral neuropathy. Various other patents contemplate the use of a neurotoxin for additional applications such as, neuromuscular disorders (6,872,397), essential tremor (6,861,058), pancreatitis (6,843,998), muscle spasm (6,841,156), sinus headache (6,838,434), endocrine disorders (6,827,931), priapism (6,776,991), thyroiditis (6,773,711), cardiovascular disease (6,767,544), thyroid disorders (6,740,321), hypocalcemia (6,649,161), hypercalcemia (6,447,785), tardive dyskinesia (6,645,496), fibromyalgia (6,623,742), Parkinson's Disease (6,620,415) cerebral palsy (6,448,231), inner ear disorders (6,358,926), cancers (6,139,845), ocular disorders (6,265,379), appetite reduction ((US2004/0253274), compulsive disorders (US2004/0213814, US2004/0213813), uterine disorders ((US2004/0175399), neuropsychiatric disorders (US2003/0211121), dermatological or transdermal applications (US2004/00091880), focal epilepsy (US2003/0202990) the contents of which are expressly incorporated herein by reference in their entirety.

[0007] The patent authors have further detailed devices and methods for treating asthma with local delivery of the intact botulinum toxin in United States Patent Application 10/437,882, filed on May 13, 2003, the contents of which are expressly incorporated by reference herein in its entirety.

[0008] Due to their extreme toxicity, neurotoxins are highly controlled and can have disastrous consequences if not used and controlled properly, especially when used in vivo. In addition, due to their toxicity, the body tends to build up a resistance to their use, resulting in lower efficacy, the need for increased treatments, or the need to discontinue their use all together in certain patients.

[0009] In light of the foregoing, it would be desirable to provide methods and apparatus for delivering neurotoxins such as botulinum toxins non-toxically.

[0010] It would also be desirable to provide methods and apparatus for treating various conditions with a neurotoxin such as botulinum toxin fragments via in vivo cell permeabilization.

[0011] It would also be desirable to provide a system of devices, including catheters, trocars, needles, endoscopes, inhalers, nebulizers and aerosolizers and other mechanisms to deliver fragmented neurotoxins non-toxically.

[0012] Further, it would be desirable to couple energy delivery devices with the delivery of fragmented neurotoxins to deliver active neurotoxins, non-toxically, including catheter based energy systems, and non-invasive energy systems.

[0013] All publications and patents or patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually so incorporated by reference.

## BRIEF SUMMARY OF THE INVENTION

[0014] According to the present invention, an active fragment (sometimes referred to as a catalytic portion) of the botulinum neurotoxin (BoNT), preferably the light chain (LC) portion of BoNT, is delivered to target cells via cell membrane permeabilization. Such delivery provides a non-toxic delivery scheme for deriving a variety of clinical benefits.

Although botulinum toxins are used broadly for a variety of clinical applications, the present invention provides enhanced methods of delivery and use of the isolated active fragments or portions of the toxin.

[0015] The present invention contemplates application to all of the conditions listed herein, collectively defined as “therapeutic target conditions”, and any other conditions for which BoNT is known to or can be shown to provide a therapeutic benefit. Certain examples have been detailed below for specific applications, but it is within the scope of the present invention that the methods and devices detailed herein have specific applications to many or all of the conditions wherein the intact neurotoxin BoNT has shown or proposed to show a therapeutic benefit or effect.

[0016] In one aspect of the present invention, BoNT-LC or other active fragment is delivered with the application of energy to achieve cell membrane permeabilization.

[0017] In another aspect of the present invention methods and apparatus are provided for altering autonomic nerve function by utilizing an electric field or ultrasonic energy generated by a pulse or pulses of a designated duration and amplitude to alter tissue at the cellular level via permeabilization of the cell membrane to facilitate the translocation of the BoNT-LC to the cell cytosol.

[0018] A further aspect of the invention is to provide methods and apparatus for treating or inhibiting a variety of diseases or syndromes that have an underlying neurogenic component, by disrupting the neurogenic activities of the promoters or mediators of the disease or syndrome. Such disruption is facilitated by delivering an active fragment of botulinum toxin, such as the light chain portion of botulinum toxin serotype A (BoNT-LC/A), in the presence of an electric field or ultrasonic energy applied to permeabilize the wall of targeted cell under conditions which induce reversible poration of the cellular membrane and efficient passage of the BoNT-LC fragment to the cell cytosol, its catalytic environment.

[0019] In a further aspect of the invention, it may be desirable to provide methods and devices that utilize a non-toxic delivery mechanism to target cells to reduce the potential for an immunogenic response to the delivered toxin over time.

[0020] In a further aspect of the invention, it may be desirable to deliver the therapeutic neurotoxin fragment and energy via a catheter.

[0021] In a further aspect of the invention, it may be desirable to deliver the therapeutic neurotoxin fragment via an aerosolizer or nebulizer.

[0022] In a further aspect of the invention, it may be desirable to deliver the therapeutic neurotoxin fragment via an inhaler.

[0023] In a further aspect of the invention, it may be desirable to deliver the therapeutic neurotoxin fragment and membrane transport energy transdermally.

[0024] In a further aspect of the invention, it may be desirable to deliver the therapeutic neurotoxin fragment via a catheter, or aerosolizer or inhaler, and the energy via a catheter placed in the vicinity of the targeted cell.

[0025] In a further aspect of the invention, it may be desirable to delivery the therapeutic neurotoxin fragment and the membrane transport energy via an implantable generator and drug delivery pump.

[0026] In a further aspect of the invention, it may be desirable to deliver the therapeutic neurotoxin fragment via a catheter, or aerosolizer (nebulizer) or inhaler, and the energy via an external energy source adapted to target the applied energy in the vicinity of the targeted cell.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Further features of the invention, its nature and various advantages will be more apparent from the accompanying drawings and the following detailed description, in which:

[0028] Figure 1 – depicts a schematic of the creation of neurotoxin Botulinum Toxin Type A (BoNT/A), including the light chain (LC) fragment or portion.

[0029] Figure 2A – depicts a schematic of a target cell, including the cell membrane, and inner cellular matrices.

[0030] Figure 2B – depicts a schematic of the target cell wherein LC molecule has been introduced.

[0031] Figure 3A-3B – depicts a the target cell of Figure 2 showing application of an energy field (EF) to produce permeabilization or pores (P) in the cell membrane, and introduction of the LC fragment therethrough.

[0032] Figure 4 – depicts a schematic of a cell wherein the energy field has been discontinued, and neurotransmission of the cell has been effectively blocked.

[0033] Figures 5, 5A-5B – depicts various embodiments of a delivery device of the present invention utilizing multiple energy transmission elements and an energy transmission system.

[0034] Figures 6A-D – depict various electrode catheter configurations adapted to deliver energy or energy and therapeutic agents to target tissue.

[0035] Figure 7 – depicts an alternative embodiment of the present invention wherein one of the multiple energy transmission elements is placed at the targeted cell site, and the other in a location remote therefrom.

[0036] Figure 8 - depicts an embodiment of the present invention utilizing an ultrasound element on a catheter device.

[0037] Figure 9 - depicts an embodiment of the present invention utilizing an inhaler with an in vivo energy delivery source.

[0038] Figure 10 - depicts an interstitial method of use of the present invention.

[0039] Figure 11 – depicts an embodiment of the present invention utilizing an aerosolizing element.

[0040] Figure 12 – depicts a fully implantable pulse generator, lead and agent delivery pump of the present invention.

[0041] Figure 13 – depicts an embodiment of the present invention utilizing an external energy delivery source applied to the therapeutic agent applied in the vicinity of a targeted cell.

[0042] Figure 14 – depicts an embodiment of the present invention wherein the energy and therapeutic agent are delivered transdermally.

[0043] Figure 15 – depicts a method of use of a noninvasive agent delivery device coupled with a non-invasive energy source for treating a lumen or tract of the respiratory system.

#### DETAILED DESCRIPTION OF THE INVENTION

[0044] The present invention is directed to methods and apparatus for targeting the non-toxic delivery of a fragment of a neurotoxin, while still maintaining the catalytic or toxic effect of the neurotoxin fragment once it is non-toxically delivered to its targeted cell. For purposes of this specification, the term “non-toxic”, “non-toxically” and the like refer to the state of the fragment molecule prior to delivery to a target location. In this description, the fragment neurotoxin is intended to retain its toxic effect once delivered to its catalytic environment; the intracellular matrix or cytosol of the targeted cell.

[0045] Devices and methods of the present invention may be directed to suitable “targeted regions” such as muscle cells in various regions of the body related to the various “therapeutic target conditions” or syndromes to be treated, as detailed in this specification above. Some particular examples include targeting mucosal and muscular lining of the lung, cholinergic cells in the region of tumors, myofacial regions, vascular smooth muscle cells, musculoskeletal regions and the like.

[0046] According to the present invention, energy fields (EF) may be applied to target regions in conjunction with the delivery of a fragmented neurotoxin such as BoNT-LC to facilitate the transfer of the neurotoxin fragment into the targeted cell, non-toxically via in vivo target cell permeabilization.

5 [0047] Use of Isolated Light Chain of Botulinum Neurotoxins. Generally, the BoNT molecule is synthesized as a single polypeptide chain of 150kD molecular weight. The neurotoxin is then exposed to enzymes, either during cultivation of the *Clostridium botulinum* organism or subsequent to purification of the toxin, wherein specific peptide bonds are cleaved or "nicked" resulting in the formation of a dichain molecule referred to as BoNT. As  
10 shown in Figure 1, dichain neurotoxin is composed of a light chain region 50kD molecular weight linked by disulfide bonds to a heavy chain 100kD molecular weight (Kistner, A., Habermann, E. (1992) *Naunyn Schmiedebergs Arch. Pharmacol.* **345**, 227-334). When the light chain is separated from the heavy chains of botulinum toxin, neither chain is capable of blocking neurotransmitter release, however, the light chain alone is capable of blocking  
15 acetylcholine release if transported directly into the cell cytosol. (Ahnert-Hilger, G., Bader, M.F., Bhakdi, S., Gratzl, M. (1989) *J. Neurochem.* **52**, 1751-1758 and Simpson, L.L. (1981) *Pharmacol. Rev.* **33**, 155-188.) Focusing on the light chain, the isolation or separation process essentially renders the light chain "non-toxic" in a general environment, while still maintaining its effect or toxicity, once it is transported through the target cell membrane.

20 [0048] Over the past several years, the separation and purification of the light chain and heavy chain of BoNT has seen significant development activity. In the case of the heavy chain (HC), researches are interested in its ability to bond with a target cell and deliver certain molecules into that cell. For example, various drug delivery applications have been suggested, for example, using the HC to bind to tPA so that a patient could inhale the HC-  
25 bound tPA allowing it to cross the membrane of the lungs and be transported into the bloodstream for anticoagulation. Of particular interest to the present invention are the efforts to isolate and purify the light chain (LC) of the botulinum molecule. In its isolated and purified form, all HC elements are removed, rendering the LC incapable of crossing the cell membrane without assistance. This renders the LC a non-toxic protein to the cell  
30 environment, while still maintaining its encoded toxicity by, once it is effectively delivered to its appropriate catalytic environment; the cell cytosol.

[0049] Various groups have been active in the area of isolation and purification. For example, companies such as Metabiologics, a group affiliated with the University of Wisconsin, the Center for Applied Microbiology and Research (CAMR), a division of the UK Health Protection Agency, List Biological Laboratories, Inc. of California, and other  
5 research groups throughout the world. Many of these companies provide purified preparations of botulinum neurotoxins from *Clostridium botulinum* types A and B. List Laboratories in particular provides recombinantly produced light chains from both types A, B, C, D and E.

[0050] According to the present invention, the therapeutic use and delivery of the light  
10 chain only may significantly improve the safety profile of certain applications of therapies utilizing BoNT. BoNT are some of the most lethal toxins known to man. All concerns about migration of the neurotoxin into unintended regions, and harm or toxicity to the patient or physician are eliminated by storing, handling, injecting and metabolizing the light chain only. In the absence of a specific membrane binding technology, the LC is completely non-toxic.

15 In certain applications, such as the treatment of asthma, this is of critical import. In using BoNT to treat asthma, a large quantity of the purified LC substance may be introduced directly into the lung, and then specifically transported to target cells in the exact location and only during the period of use of application of the membrane transport technology, such a cell membrane permeabilization by energy. Once the membrane transport technology has been  
20 removed, turned off or otherwise inactivated, the remaining LC which has not been transported into target cells can simply be removed from the body by standard biologic processes for expelling foreign materials, e.g. coughing, immune system or lymphatic system transport and the like.

[0051] In addition, therapeutic use of only the LC of the neurotoxin BoNT may reduce the  
25 likelihood of the body developing an immunogenic response to the therapy that is seen with delivery of the intact toxin. This could be a major advantage in light of the repetitive application or injection of the toxin that is required to maintain a therapeutic effect.

[0052] Non-Toxic Membrane Transport Mechanisms. To date, the main application of purified or isolated light chain has been the study of its mechanism of action. To further this  
30 research, literature has reported the use of certain detergent based permeabilization techniques to deliver fragment BoNT (Bittner MA, DasGupta BR, Holz RW. Isolated light chains of botulinum neurotoxins inhibit exocytosis. Studies in digitonin-permeabilized

chromaffin cells. J Biol Chem 1989 Jun 25;264(18):10354–10360.) Further reference to the mechanism of permeability of cell membranes to deliver botulinum toxin are mentioned in United States Patent 6,063,768 to First, and United States Patent No. 6,632,440 to Quinn, Chaddock, et al “Expression and Purification of Catalytically Active Non-Toxic

5 Endopeptidase Derivatives of Clostridium botulinum toxin type A”, *Protein Expression and Purification*, 25 (2002) 219-228, contemplating the insertion of the light chain of BoNT into a target cell without the heavy chain for purposes of deriving vaccines or in bench top studies of cell mechanisms of action. The contents of these references are expressly incorporated by reference in their entirety. None of the teachings contemplate a delivery of a fragment of  
10 neurotoxin using a clinically acceptable permeabilization technique in vivo for therapeutic uses as is contemplated by the present invention.

[0053] For purposes of this specification, the term “poration” includes various forms of electroporation, such as the use of pulsed electric fields (PEFs) , nanosecond pulsed electric fields (nsPEFs), ionophoresis, electrophoresis, electroporation, as well as other  
15 energy mediated permeabilization, including sonoporation (mediated by ultrasonic or other acoustic energy), and/or combinations thereof, to create temporary pores in a targeted cell membrane. Similarly, the term “electrode” or “energy source” used herein, encompasses the use of various types of energy producing devices, including x-ray, radiofrequency (RF), DC current, AC current, microwave, ultrasound, adapted and applied in ranges to produce  
20 membrane permeabilization in the targeted cell.

[0054] Reversible electroporation, first observed in the early 1970’s, has been used extensively in medicine and biology to transfer chemicals, drugs, genes and other molecules into targeted cells for a variety of purposes such as electrochemotherapy, gene transfer, transdermal drug delivery, vaccines, and the like.

25 [0055] In general, electroporation may be achieved utilizing a device adapted to activate an electrode set or series of electrodes to produce an electric field. Such a field can be generated in a bipolar or monopolar electrode configuration. When applied to cells, depending on the duration and strength of the applied pulses, this field operates to increase the permeabilization of the cell membrane and reversibly open the cell membrane for a short period of time by  
30 causing pores to form in the cell lipid bilayer allowing entry of various therapeutic elements or molecules, after which, when energy application ceases, the pores spontaneously close without killing the cell after a certain time delay. As characterized by Weaver,

*Electroporation: A General Phenomenon for Manipulating Cells and Tissues* Journal of Cellular Biochemistry, 51:426-435 (1993), short(1-100 $\mu$ s) and longer (1-10ms) pulses have induced electroporation in a variety of cell types. In a single cell model, most cells will exhibit electroporation in the range of 1-1.5V applied across the cell (membrane potential).

5    **[0056]**    In addition, it is known in the art that macromolecules can be made to cross reversibly created pores at voltages of 120V or less applied to cells for durations of 20 microseconds to many milliseconds. For applications of electroporation to cell volumes, ranges of 10 V/cm to 10,000 V/cm and pulse durations ranging from 1 nanosecond to 0.1 seconds can be applied. In one example, a relatively narrow ( $\mu$ sec) high voltage (200V)pulse  
10    can be followed by a longer (>msec) lower voltage pulse (<100V). The first pulse or pulses open the pores and the second pulse or series of pulses assist in the movement of the BoNT-LC across the cell membrane and into the cell.

**[0057]**    Certain factors affect how a delivered electric field will affect a targeted cell, including cell size, cell shape, cell orientation with respect to the applied electric field, cell  
15    temperature, distance between cells (cell-cell separation), cell type, tissue heterogeneity, properties of the cellular membrane and the like.

**[0058]**    Various waveforms or shapes of pulses may be applied to achieve electroporation, including sinusoidal AC pulses, DC pulses, square wave pulses, exponentially decaying waveforms or other pulse shapes such as combined AC/DC pulses, or DC shifted RF signals  
20    such as those described by Chang in *Cell Poration and Cell Fusion using and Oscillating Electric Field*, Biophysical Journal October 1989, Volume 56 pgs 641-652, depending on the pulse generator used or the effect desired. The parameters of applied energy may be varied, including all or some of the following: waveform shape, amplitude, pulse duration, interval between pulses, number of pulses, combination of waveforms and the like.

25    **[0059]**    A schematic example of the methods of the present invention are shown in Figures 2-4 in a simplified single cell model. A targeted cell is shown in Figure 2A. Fragmented neurotoxin such as BoNT-LC is introduced into the vicinity of the targeted cell as depicted in Figure 2B. An energy field (EF) is applied in accordance with the present invention resulting in the transfer of the BoNT-LC to the intracellular matrix (cytosol) as shown in Figures 3A  
30    and 3B. Once this transfer has occurred, the release of neurotransmitters of the target cell are then blocked or disrupted, and once energy application is discontinued, the pores in the cell membrane recover or close as depicted in Figure 4.

[0060] Of particular interest for application in certain therapeutic target conditions is the developing field of sonoporation. Just as pulses of high voltage electricity can open transient pores in the cell membrane, ultrasonic energy can do the same. See for example Guzman et al. "Equilibrium Loading of Cells with Macromolecules by Ultrasound: Effects of Molecular Sizing and Acoustic Energy", *Journal of Pharmaceutical Sciences*, 91:7, 1693-1701, which examines the viability of ultrasound to deliver molecules of a variety of sizes into target cells. In addition, techniques for nebulizing fluids and aqueous drugs are well known in the art, and as such, devices of the present invention may be adapted to introduce a BoNT-LC solution to a target region, such as the lung and then effect selective membrane transport of the BoNT-LC into the cell using sonoporation.

[0061] For example, United States Patent 6,601,581 to Babaev, hereby incorporated by reference in its entirety, describes certain techniques for delivering therapeutic agents using ultrasound for pulmonary delivery via an aerosolizing technique. Further, Guzman, et al, depicts delivery of molecules from a low of 62Da up to 464 kDa (a range of 0.6-18.5nm radius). Since the LC of the botulinum toxin is in the 50kDa range, the LC would be very susceptible to sonoporetic delivery. Furthermore, Guzman, et al also showed that for all size ranges tested, levels of macromolecule within the cell reached thermodynamic equilibrium with the extracellular environment, and the cell uptake also depended on the energy delivered, as expressed in  $\text{J}/\text{cm}^2$ . As such, the sonoporetic delivery of LC to the targeted regions may be controlled by adjusting the concentration of the LC exposed to the target region (e.g. wall or membrane of the lung), the energy delivered to the target region, or both.

[0062] Catheter Devices. To achieve the goals of the present invention, it may be desirable to employ methods and apparatus for achieving cell membrane permeabilization via the application of an energy source, either from a catheter located directly in the vicinity of the targeted cells, or an externally focused energy system. For purposes of this specification, the term "catheter" may be used to refer to an elongate element, hollow or solid, flexible or rigid and capable of percutaneous introduction to a body (either by itself, or through a separately created incision or puncture), such as a sheath, a trocar, a needle, a lead. Further descriptions of certain electroporation catheters are described in United States Patent Application (Attorney Docket No. 020979-003500US) filed on the same day as the present application, the full disclosures of which are expressly incorporated herein by reference.

**[0063]** Figures 5 and 5A-5B depict a system utilizing an electroporation catheter for selective electroporation of targeted cells. In certain configurations of the present invention, voltages may be applied via the electroporation catheter to induce reversible electroporation at the same time as the catheter delivers the fragmented neurotoxin to the targeted region.

5 **[0064]** Referring to Figure 5, electroporation catheter system comprises a pulse generator such as those generators available from Cytropulse Sciences, Inc. (Columbia, MD) or the Gene Pulser Xcell (Bio-Rad, Inc.), or IGEA (Carpi, Italy), electrically connected to a catheter having a proximal end and a distal end and adapted for minimally invasive insertion into the desired region of the body as described herein. The catheter further comprises an  
10 electroporation element at the distal end thereof. The electroporation element consists of a first and second electrode operatively connected to the pulse generator for delivering the desired number, duration, amplitude and frequency of pulses to affect the targeted cells. These parameters can be modified either by the system or the user, depending on the location of the catheter within the body (intervening tissues or structures), and the timing and duration  
15 of reversible cell poration desired.

**[0065]** Figure 5A depicts an arrangement of electrodes that produces an electric field concentrated in a lateral direction from the catheter body whereas, Figure 5B shows a device constructed to create a more uniform electric field about the shaft of the catheter body. Further catheter device and electrode configurations are shown in Figures 6A-6D, including,  
20 Figure 6A depicting an elongate catheter having a first and second electrode near the distal tip thereof, and including a monitoring or stimulation electrode in the vicinity of the active porating electrodes for localizing the treatment area. In some embodiments, the monitoring or stimulating function may be performed by one or more of the treatment electrodes. The catheter device may have an optional sharp tip to facilitate percutaneous introduction. Figure  
25 6B is a similar catheter device, but is further adapted to be steerable, or articulate at a region near the distal end of the device. Such steering ability enables the operator to introduce the device into tight or tortuous spaces (such as the bronchial passages, or cardiovascular vessels) so that optimal placement of the device at the target location may be achieved.

**[0066]** Figure 6C depicts a further embodiment of the catheter device described above, that  
30 includes an injection element to allow for the injection of a therapeutic agent such as a fragmented neurotoxin before, during or after the application of the pulsed energy or electroporation. The injection element may be a needle as shown in Figure 6c, an infusion

port, or other infusion means. Figure 10 depicts the use of a catheter of Figure 6C to treat bronchial tissue in the lung for a variety of respiratory ailments such as asthma.

[0067] Figure 6D depicts an alternative embodiment of the present invention, showing a catheter device having electrode elements that are adapted to extend laterally from the main catheter body, and in some cases, penetrate the surrounding tissue prior to application of energy. In doing so the depth and direction of the energy field created by the electroporative process, may be further controlled.

[0068] Figure 7 depicts the use of a catheter device of the present invention for treatment of a respiratory tract, by positioning at least one electrode (E1) at the target region, and a second electrode (E2) remote from the target region, the target region being positioned between E1 and E2, such that activation of the electrodes produces an energy field (EF) therebetween, the size and intensity of which can be controlled by the placement of the electrodes relative to each other and the targeted region.

[0069] Figure 8 depicts an embodiment of the present invention utilizing an ultrasonic element that may be particularly useful in delivery of the BoNT-LC to bronchial tissue (lung) that provides a broad but targeted transport of the LC across the epithelial and goblet cell walls. In this device, ultrasound energy is delivered to the distal end of the catheter device via an ultrasonic waveguide that is operatively connected to an ultrasound energy source (U/SES). The LC fragment would be delivered via the same lumen as the waveguide, or via a separate lumen that exits the distal tip of the device. In operation, the ultrasonic energy would cause the LC solution to be nebulized, forming a mist within the lung, as shown in Figure 11. The mist itself, in the appropriate concentrations, may act as an ultrasound coupler, conveying the ultrasonic energy to the wall of the lung or other targeted cellular structures, causing sonoporation of the targeted cells whereby the LC fragment is transmitted across the cell membranes to become an effective neurotransmitter blocker. In an alternative embodiment, an ultrasonic transducer may be located directly at the tip of the delivery device, eliminating the need for a wave guide. Various catheters useful for delivering vibrational energy to tissue are described in United States Patent 6,361,554 and 6,464,680 to Briskin, the contents of which are expressly incorporated herein by reference in their entirety, for various therapeutic effects, such as enhancing cellular absorption of a substance.

[0070] Since air is a very effective insulator against transmission of ultrasonic energy, the treatment area in the lung may be more precisely controlled by the concentration of the LC

mist and the intensity of the ultrasonic energy. A fairly steep drop off in energy delivery would occur as mist concentration diffused, effectively protecting areas outside the predetermined radius surrounding the distal end of the delivery device. According to the present invention, since no functional neurotoxin exists without an effective membrane transport technology, terminating the energy application leaves a harmless mist that is then coughed up (if resident in the lungs) or otherwise metabolized and excreted by the body.

[0071] Any of the catheter devices described herein, or described in the contemporaneously filed United States Patent Application (Attorney Docket No. 020979-003500US) previously incorporated by reference in its entirety, may be adapted to include an energy delivery element such as those described herein for purposes of providing a membrane transport system for delivery of a fragment of neurotoxin. In addition, certain catheter devices and methods such as those set forth in United States Patents 5,964,223 and 6,526,976 to Baran may be adapted to include energy transmission elements capable of producing a porative effect at the cellular level, including electrodes, ultrasonic elements and the like, for treatment in the respiratory tract.

[0072] Furthermore, any of the foregoing systems may include electrodes or other monitoring systems either located on the treatment catheter, or external to the patient, to determine the degree of treatment to the region, including, thermocouple, ultrasound transducers, fiberoptics, sensing or stimulating electrodes. Further, it may be desirable to incorporate multiple pairs of electrodes that may be activated in pairs, in groups, or in a sequential manner in order to maximize the desired shape of the energy field (EF) while minimizing the field strength requirements.

[0073] Implantable Devices. Just as energy may be delivered to a targeted region to facilitate the delivery of fragmented neurotoxin via a catheter system, it is also within the scope of the present invention to deliver neurotoxins via an implantable system, including a pulse generator, lead and drug pump as depicted in Figures 12A-12D. A neuromodulation system may be fully implantable, having a pulse generator and a power supply or battery as shown in Figure 12C, and be operatively connected to a programmable drug delivery pump such as those shown in Figures 12A and 12B, including a reservoir in which the BoNT-LC is stored for delivery over time using the principles of the present invention and technology of the programmable drug pump.

[0074] Examples of useful implantable devices of the present invention are, devices such as those set forth in United States Patent 5,820,589 to Torgerson et al, the entire contents of which are hereby incorporated by reference, the SynchroMed® programmable pump available from Medtronic, Inc. (Minneapolis, MN), and the neurostimulation units such as the RESTORE® or SynergyPlus® available from Medtronic, Inc., modified if necessary to delivery the desired voltage range for cell membrane permeabilization. Implantation of the neurostimulation device is further described in US Patent 6,847,849, incorporated herein by reference in its entirety.

[0075] The non-toxic nature of the BoNT in the absence of applied energy, makes it possible to contemplate placing a bolus of neurotoxin in the body of a patient in what might otherwise be a toxic amount. This is particularly advantageous, since the traditional treatment regime using neurotoxins, is typically repeat injections of the toxins every 3 to 6 months and sometimes more frequently depending on the application. Certainly in more chronic conditions such as chronic pain, tremor, spasm, palsy and the like, such a fully implantable system may be highly desirable.

[0076] Non-Invasive Devices. It is within the scope of the invention to deliver either the energy or the therapeutic BoNT-LC non-invasively, or both. For example, Figure 13 depicts delivery of the BoNT-LC via a catheter placed in the bronchial passageway with the energy field(EF) delivered from outside the patient in the form of an energy system (ES) such as focused ultrasound (HIFU), stereotactic x-ray beams, magnetic resonance transmission, and the like. As detailed in United States Patents 6,626,855 and 6,719,694 to Weng, the contents of which are expressly incorporated herein by reference in their entirety, an ultrasound beam can be controlled from outside the patient to focus the ultrasound beam in the desired location and intensity. For use in the present invention, it may be desirable to pulse or otherwise attenuate the ultrasound beam to achieve reversible cellular poration at the targeted site. Further, due to its non-toxic state, the BoNT-LC may be inhaled by the patient using a standard inhaler device such as those using pressurized aerosols known as metered dose inhalers (MDI) available from Cardinal Health (Somerset, NJ), the OPTIHALER® available from National Allergy Supply Incorporated (Georgia, USA), or a nebulizer breathing machine such as a Pari DURANEb 3000 portable nebulizer available from Medinfinity, Co. (Fountain Valley, CA). In addition, certain technology currently under development employing thermal aerosols, such as the STACCATO™ vaporization technology from Alexza Molecular Delivery (Palo Alto, CA) may also be useful within the scope of the

present invention. Such devices may be used as depicted in Figure 9 of Figure 13 in the context of treating a respiratory ailment such as asthma.

[0077] A combination of these non-invasive approaches may also be advantageous as shown in Figure 15, wherein an non-invasive inhaler is used to deliver the BoNT-LC to the target region (such as the lung), and the energy delivered to the target region is also non-invasive such as the focused ultrasound (HIFU), stereotactic x-ray, or magnetic resonance transmission as previously described. Due to its non-invasive technique, this approach may have broad appeal to a large patient population, including pediatric use, on an outpatient basis in a clinic designated for the treatment of specific respiratory ailments.

[0078] In a further aspect of the present invention, the fragmented molecule BoNT-LC may be delivered intravenously to a patient to achieve a systemic affect. A non-invasive energy application device, such as those described above, may then be targeted at the area of interest to porate the target area, thereby locally delivering the BoNT-LC to the region sufficiently porated by the applied energy.

[0079] Cosmetic and Myofacial Applications. For some conditions, it may be desirable to apply the energy field from the surface of the skin to produce a porative effect, while injecting the BoNT-LC fragment into the targeted facial muscles as shown in Figure 14. In operation, an injection device places the BoNT-LC in the muscle to be treated (target region), and an energy transmission device, in this particular case an ultrasonic pen with a single, or a series of ultrasonic elements located on the distal end and coupled to an energy transmission system (ETS), follows along the target region to controllably discharge the BoNT-LC fragments to the targeted cells leaving a highly controlled treated region. In some instances for treatments around the eye, it may be desireable to limit the penetration of the BoNT-LC to dermal or subdermal layers. In these applications, BoNT-LC may be applied transdermally with ultrasound assistance using techniques similar to those set forth in US Patent 4,767,402 to Kost the contents of which is expressly incorporated herein in its entirety or through transdermal electroporation.

[0080] Intraluminal Devices. It may further be advantageous to position catheters of the present invention through vessels in the body to direct them to various regions to affect neurotransmitters in the cardiovascular system. Intraluminal catheters such as those shown in United States Patent Applications 2001/0044596 to Jaafar and 2002/0198512 to Seward,

hereby incorporated by reference in their entirety, may be used in this application of the present invention.

**[0081] Treatment Enhancements.** In some applications of the present invention, it may be desirable to assess the appropriate location for the therapy prior to treatment, the therapeutic effect as it is delivered, and ultimately the resulting effect. To achieve this, once the treatment device is in place adjacent the tissue to be treated, the energy generator may be activated, causing an energized field to be generated in the target area. Prior to activation of therapeutic voltages and agent, stimulation using one or more electrodes may be used to elicit a nerve response or reflex. By observing the nerve response, a target treatment location can be confirmed. Similarly, once the therapy has been delivered, a similar stimulation response may be sought, to determine presence or lack of neurogenic response.

**[0082]** In operation, effects of electroporation and delivery of a therapeutic dose of BoNT-LC may be selective due to the cellular structure and orientation of the targeted cells. For example, targeted cells may be preferentially affected due to size, avoiding smaller or cross-oriented tissue cells.

**[0083]** In a further aspect of the present invention, the method of delivering the LC fragment of the BoNT molecule may include the use of a media that contains microspheres or microbubbles, such as Optison<sup>TM</sup> sold by GE Healthcare ([www.amershamhealth-us.com/optison/](http://www.amershamhealth-us.com/optison/)). Delivery of an ultrasound energy (or other form of energy, for example, laser, RF, thermal, energy) to the media causes the microspheres to rupture, which causes a release of energy toward the targeted region. Such a technique may assist in the desired porative effect by reducing the amount of applied energy required to create poration in the targeted cell membrane. *Bioeffects Caused by Changes in Acoustic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius*, Guzman, et al. *Ultrasound in Med. & Biol.*, Vol. 29, No. 8, pp. 1211-1222 (2003). In an alternative embodiment, the LC fragment may actually be contained or encapsulated within a microsphere to assist in delivery. Such enhancing elements may be delivered prior to energy application or during energy application.

**[0084]** In a further aspect of the present invention, it may be advantageous to heat the targeted cells or surrounding tissue by either applying thermal energy directly to the region, or directing a heated fluid, such as saline to the region through an injection element, to aid the cell poration process. Other substances may also be injected to aid in the transmission of the

BoNT-LC into the intracellular membrane, such as amino acids, detergents or other agents that may facilitate the catalytic activity of the LC, in addition to the applied energy.

[0085] Although various illustrative embodiments of the present invention are described above, it will be evident to one skilled in the art that various changes and modifications may be made without departing from the scope of the invention. It will also be apparent that  
5 various changes and modifications may be made herein without departing from the invention. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.

WHAT IS CLAIMED IS:

- 1                   1.       A method for treating various conditions affected by neurogenic  
2 function in a targeted region of mammalian cells, comprising:  
3                   delivering an active fragment of BoNT-LC to the vicinity of a cell in the  
4 targeted region;  
5                   applying energy to the cells under conditions which cause a reversible  
6 poration in the cell membranes to permit delivery of the active fragment.
- 1                   2.       A method of claim 1, wherein the active fragment comprises an  
2 amount of BoNT-LC therapeutically effective to inhibit a neurogenic pathway associated  
3 with the neurogenic function.
- 1                   3.       A method of claim 1 wherein the active fragment is BoNT-LC derived  
2 from at least one of the botulinum toxins A, B, C, D, E, F or G.
- 1                   4.       A method of claim 2, wherein the neurogenic pathway is associated  
2 with and contributes to at least one symptom of asthma.
- 1                   5.       A method of claim 1, wherein the delivery is achieved using a catheter.
- 1                   6.       A method of claim 5 wherein the delivery is achieved using an  
2 aerosolizer.
- 1                   7.       A method of claim 5 wherein the delivery is achieved using an inhaler.
- 1                   8.       A method of claim 6, wherein the delivery is achieved transdermally.
- 1                   9.       A method of claim 1, wherein the energy applied to the targeted region  
2 is an electric pulse of between 1V and 500V.
- 1                   10.      A method of claim 1 wherein the energy applied to the targeted region  
2 is ultrasonic.
- 1                   11.      A method of claim 1 wherein the energy applied to the targeted region  
2 is an electric pulse.
- 1                   12.      A method of claim 11 wherein the electric pulse is an RF signal.

- 1                    13.     A method of claim 11, wherein the RF signal is pulsed for durations  
2     between 5 microseconds to 100 milliseconds.
- 1                    14.     A method of claim 11, wherein the electric pulse is produced by a DC  
2     power source.
- 1                    15.     A method of claim 11, wherein the electric pulse is produced by an AC  
2     power source.
- 1                    16.     A method of claim 1 wherein the energy applied to the targeted region  
2     is an x-ray beam.
- 1                    17.     A method of claim 1 wherein the energy applied to the targeted region  
2     is focused ultrasound.
- 1                    18.     A method of claim 1 wherein the energy applied to the targeted region  
2     is microwave.
- 1                    19.     A method of claim 2, wherein the neurogenic pathway is associated  
2     with and contributes to at least one symptom of pain.
- 1                    20.     A method of treating a respiratory ailment, comprising the steps of:  
2                    providing an amount of BoNT-LC comprising at least one molecule of BoNT-  
3     LC, and  
4                    delivering the BoNT-LC in conjunction with an energy source to a region of  
5     the respiratory system.

**SYSTEMS AND METHODS FOR  
DELIVERY OF A THERAPEUTIC AGENT**

**ABSTRACT OF THE DISCLOSURE**

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

60544314 v1




Fig 1




FIG 2A




FIG 2B




FIG 3A




FIG 3B




FIG 4










FIG 5








FIG 7




FIG 13

U/S TREATMENT 8




FIG 8




FIG 11




FIG 9




FIG 10




**FIG 12A**




**FIG 12B**




**FIG 12C**



FIG 12D




FIG 14




FIG 15

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

## **Application Data Sheet**

### **Application Information**

Application number::  
Filing Date:: 07/22/05  
Application Type:: Provisional  
Subject Matter:: Utility  
Title:: SYSTEMS AND METHODS FOR DELIVERY  
OF A THERAPEUTIC AGENT  
  
Attorney Docket Number:: 020979-003400US  
Request for Early Publication:: No  
Request for Non-Publication:: No  
Total Drawing Sheets:: 13  
Small Entity?: Yes  
Petition included?: No  
Secrecy Order in Parent Appl.: No

### **Applicant Information**

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: MARK  
Middle Name:: E.  
Family Name:: DEEM  
City of Residence:: Mountain View  
State or Province of Residence:: CA  
Country of Residence:: US  
Street of Mailing Address:: 685 Sierra Avenue  
City of Mailing Address:: Mountain View  
State or Province of mailing address:: CA  
Country of mailing address:: US  
Postal or Zip Code of mailing address:: 94041

|                                         |                    |
|-----------------------------------------|--------------------|
| Applicant Authority Type::              | Inventor           |
| Primary Citizenship Country::           | US                 |
| Status::                                | Full Capacity      |
| Given Name::                            | HANSON             |
| Family Name::                           | GIFFORD            |
| City of Residence::                     | Woodside           |
| State or Province of Residence::        | CA                 |
| Country of Residence::                  | US                 |
| Street of Mailing Address::             | 3180 Woodside Road |
| City of Mailing Address::               | Woodside           |
| State or Province of mailing address::  | CA                 |
| Country of mailing address::            | US                 |
| Postal or Zip Code of mailing address:: | 94062              |

#### **Correspondence Information**

|                                  |       |
|----------------------------------|-------|
| Correspondence Customer Number:: | 20350 |
|----------------------------------|-------|

#### **Representative Information**

|                                  |       |
|----------------------------------|-------|
| Representative Customer Number:: | 20350 |
|----------------------------------|-------|

#### **Assignee Information**

|                                         |                     |
|-----------------------------------------|---------------------|
| Assignee Name::                         | The Foundry Inc.    |
| Street of mailing address::             | 199 Jefferson Drive |
| City of mailing address::               | Menlo Park          |
| State or Province of mailing address::  | CA                  |
| Country of mailing address::            | US                  |
| Postal or Zip Code of mailing address:: | 94025               |

PATENT APPLICATION SERIAL NO. \_\_\_\_\_

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
FEE RECORD SHEET

07/27/2005 FFANAI2 00000143 201430 60702077

01 FC:2005 100.00 DA

PTO-1556

(5/87)